Trial Profile
A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacteraemia; Bacterial endocarditis; Staphylococcal infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 28 Mar 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 01 Sep 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 01 Sep 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.